



Find better in-licensing opportunities with **PhD-led, AI-enhanced biopharma portfolio strategy**

Business development teams can only evaluate a fraction of the opportunity space

Time and resource constraints mean most teams can interrogate only a subset of in-licensing opportunities, which means the best options can get missed. Language barriers compound the issue, making opportunities in high-growth markets like China harder to identify.

No more deals missed due to capacity constraints or language barriers

Scitaris' validated biopharma-specific AI agent, *Scitaris-AI*, overcomes these challenges. Delivering **~95% accuracy, ~94% reproducibility**,¹ and the speed of AI workflows, the agent enables us to deliver:


- **Deeper, broader opportunity coverage in the same timeframe:** truly comprehensive option space analysis ensures best-fit assets never slip from view.
- **Real-time, continuous option space monitoring:** continuous news and data integration means recommendations are based on an up-to-the-minute market picture.
- **Analysis that transcends language barriers:** integrated data and news sources across key markets, including China, minimizes the risk of missed opportunities.

The same expert-led process, now with **AI-powered breadth and depth**

Scitaris-AI translates Scitaris' validated consulting methodology into an agentic framework, powered by the proprietary data, SOPs, and decision criteria our PhD-level consultants use.

Our AI-enabled approach rests on three foundations:

- **Client-focused agent optimization:** decision criteria, competitive benchmarks, and transactability thresholds are tailored to your therapeutic focus, geographic priorities, deal structure, and portfolio gaps.
- **Automated, trustworthy first-pass evaluations:** the entire opportunity space is assessed and ranked by *Scitaris-AI* with **~95% accuracy and ~94% reproducibility.**¹
- **Expert-in-the-loop validation and recommendation:** PhD-level consultants provide inputs, interpret outputs, handle edge cases, and apply critical judgment for final strategic recommendations.



Ensure your next portfolio
decision is the right one

Find out how our AI-augmented
PhD-level consulting services can help.



SCITARIS
BIOPHARMA STRATEGY

References

1. Martins Costa C, Mühlhäuser W. *A biopharma-specific AI agent for high-stakes strategic decision-making. Evaluating the performance of Scitaris-AI for in-licensing opportunity assessment and beyond.* (2025)